Heidelberg Pharma's HDP-103 Shows Promise for Tough Prostate Cancer Cases
April 6, 2026 — Heidelberg Pharma presents preclinical data for HDP-103, an Amanitin-based ADC targeting metastatic prostate cancer, at AACR 2026. Promising results show efficacy in tough cases.